Review on the access to orphan drugs in Bulgaria

ICRDOD announces the publication of the updated and expanded version of its review on the access to orphan drugs in Bulgaria. The report contains 4 sections: orphan drug designation and marketing authorization; pricing, inclusion in the Positive drug list and reimbursement; mechanisms for accelerated access to innovative medicines; conclusions. There are 2 annexes, attached to the review: list of orphan drugs in EU and Bulgaria, which contains information about the trade name, ATC code, active substance, indication(s), marketing authorization holder and date of marketing authorization for each item (additionally, it is indicated whether the drug is present in the Positive drug list of Bulgaria and if it is reimbursed by public funds); list of references. You can read the review at the Registries & Statistics section.